MicroRNA-mediated drug resistance in breast cancer

Clinical Epigenetics

Volumn 2, Issue 2, 2011, Pages 171-185

  Kutanzi, Kristy R ^a   Yurchenko, Olga V ^b   Beland, Frederick A ^a   Checkhun, Vasyl F ^b   Pogribny, Igor P ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

Author keywords

Breast cancer; Drug resistance; MicroRNA

Indexed keywords

CISPLATIN; DNA METHYLTRANSFERASE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; HISTONE H3; MICRORNA; MICRORNA 125; MICRORNA 148; MICRORNA 155; MICRORNA 194; MICRORNA 20; MICRORNA 200; MICRORNA 214; MICRORNA 221; MICRORNA 222; MICRORNA 326; MICRORNA 345; MICRORNA 373; MICRORNA 375; MICRORNA 451; MICRORNA 7; PACLITAXEL; RNA; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG;

APOPTOSIS; BIOGENESIS; BREAST CANCER; CANCER PROGNOSIS; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CROSS RESISTANCE; DNA METHYLATION; DNA REPAIR; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG TARGETING; DRUG TREATMENT FAILURE; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE REPRESSION; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RNA ANALYSIS; TUMOR SUPPRESSOR GENE; UPREGULATION;

EID: 84856241901     PISSN: 18687075     EISSN: 18687083     Source Type: Journal    
DOI: 10.1007/s13148-011-0040-8     Document Type: Review

References (140)

1. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R, Howell SB (1996) Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56:3087-3090 (Pubitemid 26199755)
2. Aigner A (2011) MicroRNAs (miRNAs) in cancer invasion and metastasis: therapeutic approaches based on metastasis-related miRNAs. J Mol Med 89:445-457
3. Allen JD, van Dort SC, Buitelaar M, van Tellingen O, Schinkel AH (2003) Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res 63:1339-1344 (Pubitemid 36348714)
4. Andorfer CA, Necela BM, Thompson EA, Perez EA (2011) Micro-RNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. Trends Mol Med 17(6):313-319.
5. Ariazi EA, Ariazi JL, Cordera F, Jordan VC (2006) Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem 6:181-202
6. Baguley BC (2010) Multiple drug resistance mechanisms in cancer. Mol Biotechnol 46:308-316
7. Baker EK, El-Osta A (2003) The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer. Exp Cell Res 290:177-194 (Pubitemid 37272164)
8. Baker EK, Johnstone RW, Zalcberg JR, El-Osta A (2005) Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 24:8061-8075 (Pubitemid 41746749)
9. Bandrés E, Cubedo E, Agirre X, Malumbres R, Zárate R, Ramirez N, Abajo A, Navarro A, Moreno I, Monzó M, García-Foncillas J (2006) Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 5:29-38
10. Bar N, Dikstein R (2010) miR-22 forms a regulatory loop in PTEN/AKT pathway and modulates signaling kinetics. PLoS One 5(5): e10859
11. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-97
12. Baylin SB (2011) Resistance, epigenetics and the cancer ecosystem. Nat Med 17:288-289
13. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO, Tavaré S, Caldas C, Miska EA (2007) MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 8:R214
14. Blower PE, Verducci JS, Lin S, Zhou J, Chung JH, Dai Z, Liu CG, Reinhold W, Lorenzi PL, Kaldjian EP, Croce CM, Weinstein JN, Sadee W (2007) MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther 6:1483-1491 (Pubitemid 46954015)
15. Borchert GM, LanierW DBL (2006) RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol 13:1097-1101 (Pubitemid 44885920)
16. Bourguignon LY, Spevak CC, Wong G, Xia W, Gilad E (2009) Hyaluronan-CD44 interaction with protein kinase C (epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J Biol Chem 284:26533-26546
17. Britton DJ, Hutcheson IR, Knowlden JM, Barrow D, Giles M, McClelland RA, Gee JM, Nicholson RI (2006) Bidirectional cross talk between ERa and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat 96:131-146
18. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T (2008) A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 9:582-589 (Pubitemid 351772923)
19. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329-2334 (Pubitemid 46698581)
20. Chekhun VF, Kulik GI, Yurchenko OV, Tryndyak VP, Todor IN, Luniv LS, Tregubova NA, Pryzimirska TV, Montgomery B, Rusetskaya NV, Pogribny IP (2006) Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells. Cancer Lett 231:87-93 (Pubitemid 41779456)
21. Chekhun VF, Lukyanova NY, Kovalchuk O, Tryndyak VP, Pogribny IP (2007) Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper-and hypomethylated targets. Mol Cancer Ther 6:1089-1098 (Pubitemid 46554580)
22. Chen GQ, Zhao ZW, Zhou HY, Liu YJ, Yang HJ (2010) Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin. Med Oncol 27:406-415
23. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102(39):13944-13949 (Pubitemid 41377683)
24. Climent J, Dimitrow P, Fridlyand J, Palacios J, Siebert R, Albertson DG, Gray JW, Pinkel D, Lluch A, Martinez-Climent JA (2007) Deletion of chromosome 11q predicts response to anthracyclinebased chemotherapy in early breast cancer. Cancer Res 67:818-826 (Pubitemid 46192223)
25. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK (2009) MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 8:1055-1066
26. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 106:13820-13825
27. Dar AA, Majid S, de Semir D, Nosrati M, Bezrookove V, Kashani-Sabet M (2011) miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein. J Bio Chem 286 (19):16606-16614
28. Del Bufalo D, Biroccio A, Leonetti C, Zupi G (1997) Bcl-2 overexpression enhances the metastatic potential of a human breast cancer line. FASEB J 11:947-953 (Pubitemid 27425896)
29. Di Leva G, Gasparini P, Piovan C, Ngankeu A, Garofalo M, Taccioli C, Iorio MV, Li M, Volinia S, Alder H, Nakamura T, Nuovo G, Liu Y, Nephew KP, Croce CM (2010) MicroRNA cluster 221-222 and estrogen receptor α interactions in breast cancer. J Natl Cancer Inst 102:706-721
30. Duursma AM, Kedde M, Schrier M, le Sage C, Agami R (2008) miR-148 targets human DNMT3b protein coding region. RNA 14:872-877 (Pubitemid 351574909)
31. Egger G, Liang G, Aparicio A, Jones PA (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429:457-463 (Pubitemid 38715140)
32. Ellis LM, Hicklin D (2009) Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin Cancer Res 15:7471-7478
33. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, Volinia S, Guler G, Morrison CD, Chan KK, Marcucci G, Calin GA, Huebner K, Croce CM (2007) MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 104:15805-15810 (Pubitemid 350035380)
34. Feng L, Xie Y, Zhang H, Wu Y (2011) miR-107 targets cyclindependent kinase 6 expression, induces cell cycle G1 arrest and inhibits invasion in gastric cancer cells. Med Oncol. doi:10.1007/s12032-011-9823-1
35. Filippov V, Solovyev V, Filippova M, Gill SS (2000) A novel type of RNase III family proteins in eukaryotes. Gene 245:213-221 (Pubitemid 30125381)
36. Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP, Kouzarides T (2003) The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 278:4035-4040 (Pubitemid 36801137)
37. Gatti L, Zunino F (2005) Overview of tumor cell chemoresistance mechanisms. Methods Mol Med 111:127-148
38. Garofalo M, Croce CM (2011) microRNAs: master regulators as potential therapeutics in cancer. Ann Rev Pharmacol Toxicol 51:25-43
39. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A, Tacioli C, Pichiorri F, Alder H, Secchiero P, Gasparini P, Gonelli A, Costinean S, Acunzo M, Condorelli G, Croce CM (2009) miR-221 & 222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 16(6):498-509
40. Glasspool RM, Teodoridis JM, Brown R (2006) Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 94:1087-1092
41. Gottesman MM, Ling V (2006) The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett 580:998-1009 (Pubitemid 43185280)
42. Greene SB, Gunaratne PH, Hammond SM, Rosen JM (2010) A putative role for microRNA-205 in mammary epithelial cell progenitors. J Cell Sci 123(Pt 4):606-618
43. Guo HA, Ingolia NT, Weissman JS, Bartel DP (2010a) Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466(7308):835-840
44. Guo XB, Guo L, Ji J, Zhang J, Zhang J, Chen X, Cai Q, Li J, Gu Q, Liu B, Zhu Z, Yu Y (2010b) miRNA-331-3p directly targets E2F1 and induces growth arrest in human gastric cancer. Biochem Biophys Res Commun 398(1):1-6
45. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES (2009) Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138:645-659
46. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674
47. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ (2010) Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 251:499-505
48. Hiscox S, Morgan L, Barrow D, Dutkowskil C, Wakeling A, Nicholson RI (2004) Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). Clin Exp Metastasis 21:201-212 (Pubitemid 39158497)
49. Ingelman-Sundberg M, Rodriguez-Antona C (2005) Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philos Trans R Soc Lond B Biol Sci 360:1563-1570
50. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65:7065-7070 (Pubitemid 41161233)
51. Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T, Ménard S, Croce CM, Tagliabue E (2009) microRNA-205 regulates HER3 in human breast cancer. Cancer Res 69:2195-2200
52. Iwasa Y, Nowak MA, Michor F (2006) Evolution of resistance during clonal expansion. Genetics 172:2557-2566
53. Jedlitschky G, Leier I, Buchholz U, Barnouin K, Kurz G, Keppler D (1996) Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res 56:988-994 (Pubitemid 26065391)
54. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
55. Ji Q, Hao X, Meng Y, Zhang M, Desano J, Fan D, Xu L (2008) Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 8:266
56. Kastl L, Brown I, Schofield AC (2011) miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res Treat. doi:10.1007/s10549-011-1424-3
57. Kim VN, Han J, Siomi MC (2009) Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 10:126-139
58. Kondo N, Toyama T, Sugiura H, Fujii Y, Yamashita H (2008) miR-206 expression is down-regulated in estrogen receptor alpha-positive human breast cancer. Cancer Res 68:5004-5008
59. Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS, Cheng JQ (2008) MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol 28:6773-6784
60. Konig J, Nies AT, Cui Y, Leier I, Keppler D (1999) Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta 1461:377-394
61. Korpal M, Lee ES, Hu G, Kang Y (2008) The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 283:14910-14914
62. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF, Pogribny IP (2008) Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7:2152-2159
63. Le MT, Teh C, Shyh-Chang N, Xie H, Zhou B, Korzh V, Lodish HF, Lim B (2009) MicroRNA-125b is a novel negative regulator of p53. Genes Dev 23:862-876
64. Lee AJ, Endesfelder D, Rowan AJ, Walther A, Birkbak NJ, Futreal PA, Downward J, Szallasi Z, Tomlinson IP, Howell M, Kschischo M, Swanton C (2011) Chromosomal instability confers intrinsic multidrug resistance. Cancer Res 71:1858-1870
65. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, Kim VN (2004) MicroRNA genes are transcribed by RNA polymerase II. EMBO J 23(20):4051-4060 (Pubitemid 39472426)
66. Li J, Zhou BP (2011) Activation of β-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer 11:49
67. Li LM, Hou DX, Guo YL, Yang JW, Liu Y, Zhang CY, Zen K (2011) Role of microRNA-214-targeting phosphatase and tensin homolog in advanced glycation end product-induced apoptosis delay in monocytes. J Immunol 186(4):2552-25560
68. Liang Z, Wu H, Xia J, Li Y, Zhang Y, Huang K, Wagar N, Yoon Y, Cho HT, Scala S, Shim H (2010) Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 79:817-824
69. Liu H, Kohane IS (2009) Tissue and process specific microRNA-mRNA co-expression in mammalian development and malignancy. PLoS One 4(5):e5436
70. Liu Q, Fu H, Sun F, Zhang H, Tie Y, Zhu J, Xing R, Sun Z, Zheng X (2008) miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res 36(16):5391-5404
71. Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, Anderson B (2009) Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One 4:e6229
72. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR (2005) MicroRNA expression profiles classify human cancers. Nature 435:834-838 (Pubitemid 40839735)
73. Lujambio A, Calin GA, Villanueva A, Ropero S, Sánchez- Céspedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso MS, Faller WJ, Gallagher WM, Eccles SA, Croce CM, Esteller M (2008) A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 105:13556-13561
74. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, Westermann F, Speleman F, Vandesompele J, Weinberg RA (2010) miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12:247-256
75. Martello G, Zacchigna L, Inui M, Montagner M, Adorno M, Mamidi A, Morsut L, Soligo S, Tran U, Dupont S, Cordenonsi M, Wessely O, Piccolo S (2007) MicroRNA control of nodal signalling. Nature 449:183-188 (Pubitemid 47402367)
76. Masri S, Liu Z, Phung S, Wang E, Yuan YC, Chen S (2010) The role of microRNA-128a in regulating TGFbeta signaling in letrozoleresistant breast cancer cells. Breast Cancer Res Treat 124:89-99
77. May CD, Sphyris N, Evans KW, Werden SJ, Guo W, Mani SA (2011) Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res 13:202
78. Mei M, Ren Y, Zhou X, Yuan XB, Han L, Wang GX, Jia Z, Pu PY, Kang CS, Yao Z (2010) Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells. Technol Cancer Res Treat 9:77-86
79. Meng Z, Fu X, Chen X, Zeng S, Tian Y, Jove R, Xu R, Huang W (2010) miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice. Hepatology 52:2148-2157
80. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, Jacob S, Majumder S (2008) MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 283:29897-29903
81. Murphy CG, Modi S (2009) HER2 breast cancer therapies: a review. Biologics 3:289-301
82. Neal CL, Yao J, Yang W, Zhou X, Nguyen NT, Lu J, Danes CG, Guo H, Lan KH, Ensor J, Hittelman W, Hung MC, Yu D (2009) 14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res 69:3425-3432
83. Niemantsverdriet M, Wagner K, Visser M, Backendorf C (2008) Cellular functions of 14-3-3 zeta in apoptosis and cell adhesion emphasize its oncogenic character. Oncogene 27:1315-1319 (Pubitemid 351294692)
84. Ng WL, Yan D, Zhang X, Mo YY, Wang Y (2010) Over-expression of miR-100 is responsible for the low-expression of ATMin the human glioma cell line:M059J. DNA Repair (Amst) 9(11):1170-1175
85. Nuyten DS, Kreike B, Hart AA, Chi JT, Sneddon JB, Wessels LF, Peterse HJ, Bartelink H, Brown PO, Chang HY, van de Vijver MJ (2006) Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 8:R62
86. O'Driscoll L, Clynes M (2006) Biomarkers and multiple drug resistance in breast cancer. Curr Cancer Drug Tar 6:365-384 (Pubitemid 44033389)
87. Ovcharenko D, Kelnar K, Johnson C, Leng N, Brown D (2007) Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. Cancer Res 67:10782-10788 (Pubitemid 350145906)
88. Pan W, Zhu S, Yuan M, Cui H, Wang L, Luo X, Li J, Zhou H, Tang Y, Shen N (2010) MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1. J Immunol 184:6773-6781
89. Pan YZ, Gao W, Yu AM (2009) MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos 37:2112-2117
90. Park SY, Lee JH, Ha M, Nam JW, Kim VN (2009) miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol 16(1):23-29
91. Pogribny IP, Beland FA (2009) DNA hypomethylation in the origin and pathogenesis of human diseases. Cell Mol Life Sci 66:2249-2261
92. Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI, Kovalchuk O (2010) Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer 127:1785-1794
93. Pulukuri SM, Rao JS (2006) CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpGbinding protein MBD2. Oncogene 25:4559-4572 (Pubitemid 44175115)
94. Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, Burow ME, Ivan M, Croce CM, Nephew KP (2011) MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 30:1082-1097
95. Reardon JT, Vaisman A, Chaney SG, Sancar A (1999) Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-acetoammine- dichlorocyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 59:3968-3971 (Pubitemid 29393563)
96. Ren Y, Zhou X, Mei M, Yuan XB, Han L, Wang GX, Jia ZF, Xu P, Pu PY, Kang CS (2010) MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol. BMC Cancer 10:27
97. Roberti A, La Sala D, Cinti C (2006) Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drugresistant tumors: current views and new therapeutic prospective. J Cell Physiol 207:571-581 (Pubitemid 43668220)
98. Roth C, Rack B, Müller V, Janni W, Pantel K, Schwarzenbach H (2010) Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res 12:R90
99. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678-5685 (Pubitemid 41170290)
100. Ruan K, Fang X, Ouyang G (2009) MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett 285:116-126
101. SachdevaM, Wu H, Ru P, Hwang L, Trieu V, Mo YY (2011)MicroRNA-101- mediated Akt activation and estrogen-independent growth. Oncogene 30:822-831
102. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, Jones PA (2006) Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9(6):435-443 (Pubitemid 43832188)
103. Salter KH, Acharya CR, Walters KS, Redman R, Anguiano A, Garman KS, Anders CK, Mukherjee S, Dressman HK, Barry WT, Marcom KP, Olson J, Nevins JR, Potti A (2008) An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS One 3:e1908
104. Schultz J, Lorenz P, Gross G, Ibrahim S, Kunz M (2008) microRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res 18(5):549-557 (Pubitemid 351630945)
105. Selbach M, Schwanhäusser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N (2008) Widespread changes in protein synthesis induced by microRNAs. Nature 455:58-63
106. Shen J, DiCioccio R, Odunsi K, Lele SB, Zhao H (2010) Novel genetic variants in miR-191 gene and familial ovarian cancer. BMC Cancer 10:47
107. Siddik ZH (2002) Biochemical and molecular mechanisms of cisplatin resistance. Cancer Treat Res 112:263-284
108. Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265-7279
109. Snyder LL, Ahmed I, Steel LF (2009) RNA polymerase III can drive polycistronic expression of functional interfering RNAs designed to resemble microRNAs. Nucleic Acids Res 37:E127
110. Sorrentino A, Liu CG, Addario A, Peschle C, Scambi G, Ferlini C (2008) Role of microRNAs in drug resistant ovarian cancer cells. Gynecol Oncol 111:478-486
111. Starlard-Davenport A, Tryndyak VP, James SR, Karpf AR, Latendresse JR, Beland FA, Pogribny IP (2010) Mechanisms of epigenetic silencing of the Rassf1a gene during estrogen-induced breast carcinogenesis in ACI rats. Carcinogenesis 31:376-381
112. Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R, Sun Z, Zheng X (2008) Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett 582(10):1564-1568
113. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H (2007) Tumorsuppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci USA 104:15472-15477 (Pubitemid 47502941)
114. Thangaraju M, Kaufmann SH, Couch FJ (2000) BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines. J Biol Chem 275:33487-33496
115. Trompeter HI, Abbad H, Iwaniuk KM, Hafner M, Renwick N, Tuschl T, Schira J, Muller HW, Wernet P (2011) microRNAs miR-17, miR-20a, and miR-106b act in concert to modulate E2F activity on cell cycle arrest during neuronal lineage differentiation of USSC. PLoS One 6(1):e16138
116. Tryndyak V, Beland FA, Pogribny IP (2010) E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer 126:2575-2583
117. Tsang WP, Kwok TT (2008) Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis 13:1215-1222
118. Tsukamoto Y, Nakada C, Noguchi T, Tanigawa M, Nguyen LT, Uchida T, Hijiya N, Matsuura K, Fugjioka T, Seto M, Moriyama M (2010) microRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res 70(6):2339-2349
119. Valeri N, Gasparini P, Braconi C, Paone A, Lovat F, Fabbri M, Sumani KM, Alder H, Amadori D, Patel T, Nuovo GJ, Fishel R, Croce CM (2010) MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci USA 107:21098-21103
120. Vasudevan S, Tong Y, Steitz JA (2007) Switching from repression to activation: microRNAs can up-regulate translation. Science 318:1931-1934
121. Wada R, Akiyama Y, Hashimoto Y, Fukamachi H, Yuasa Y (2010) miR-212 is downregulated and suppresses methyl-CpG-binding protein MeCP2 in human gastric cancer. Int J Cancer 127:1106-1114
122. Wang FE, Zhang C, Maminishkis A, Dong L, Zhi C, Li R, Zhao J, Majerciak V, Gaur AB, Chen S, Miller SS (2010a) MicroRNA-204/211 alters epithelial physiology. FASEB J 24:1552-1571
123. Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J (2000) BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 14:927-939 (Pubitemid 30253002)
124. Wang Z, Li Y, Ahmad A, Asmi AS, Kong D, Banerjee S, Sarkar FH (2010b) Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. Drug Resist Updat 13:109-118
125. Winograd-Katz SE, Levitzki A (2006) Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor. Oncogene 25:7381-7390 (Pubitemid 44853429)
126. Xin F, Li M, Balch C, Thomson M, Fan M, Liu Y, Hammond SM, Kim S, Nephew KP (2009) Computational analysis of micro-RNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance. Bioinformatics 25:430-434
127. Yaqinuddin A, Abbas F, Naqvi SZ, Bashir MU, Qazi R, Qureshi SA (2008) Silencing of MBD1 and MeCP2 in prostate-cancerderived PC3 cells produces differential gene expression profiles and cellular phenotypes. Biosci Rep 28:319-326
128. Yao E, Ventura A (2011) A new role for miR-182 in DNA repair. Mol Cell 41:135-137
129. Yu Y, Wang Y, Ren X, Tsuyada A, Li A, Liu LJ, Wang SE (2010) Context-dependent bidirectional regulation of the MutS homolog 2 by transforming growth factor β contributes to chemoresistance in breast cancer cells. Mol Cancer Res 8:1633-1642
130. Yu Z, Wang C, Wang M, Li Z, Casimiro MC, Liu M, Wu K, Whittle J, Ju X, Hyslop T, McCue P, Pestell RG (2008) A cyclin D1/microRNA 17/12 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Boil 182:509-517
131. Zhang B, Steelwag EJ, Pan X (2009) Large-scale analysis reveals unique features of microRNAs. Gene 443:100-109
132. Zhang H, Li M, Han Y, Hong L, Gong T, Sun L, ZhengX (2010) Downregulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci 55:2545-2551
133. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D, Cheng JQ (2008) MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 283:31079-31086
134. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S (2010a) A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One 5:e13735
135. Zhao JJ, Lin J, Lwin T, Yang H, Guo J, KongW, Dessureault S, Moscinski LC, Rezania D, Dalton WS, Sotomayor E, Tao J, Chang JQ (2010b) microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lympohoma. Blood 115(13):2630-2639
136. Zhao X, Yang L, Hu J, Ruan J (2010c) miR-138 might reverse multidrug resistance of leukemia cells. Leuk Res 34:1078-1082
137. Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y, Xiong W, Li G, Lu J, Fodstad O, Riker AI, Tan M (2010) MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 285:21496-21507
138. Zhu S, Sachdeva M, Wu F, Lu Z, Mo YY (2010a) Ubc9 promotes breast cell invasion and metastasis in a sumoylation-independent manner. Oncogene 29(12):1763-1772
139. Zhu W, Shan X, Wang T, Shu Y, Liu P (2010b) miR-181b modulates multidrg resistance by targeting BLC2 in human cancer cell lines. Int J Cancer 128(11):2520-2529
140. Zunino F, Cassinelli G, Polizzi D, Perego P (1999) Molecular mechanisms of resistance to taxanes and therapeutic implications. Drug Resist Updat 2:351-357 (Pubitemid 30159136)